A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- MyVaccx immunotherapy treatment impact on late stage cancer disease
研究概览
简要总结
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treatment with the MyVaccx System
- •Greater than 18 years of age
- •Signature of the informed consent
排除标准
- •2 subjects treated with the MyVaccx System with known visceral disease
研究组 & 干预措施
Adenocarcinoma treated with MyVaccx
MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
干预措施: Immunotherapeutic Agents (Drug)
Adenocarcinoma treated with MyVaccx
MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
干预措施: Ablation (Device)
结局指标
主要结局
MyVaccx immunotherapy treatment impact on late stage cancer disease
时间窗: From date of treatment until the date of death from any cause up to 60 months
Time to death after the start of treatment
次要结局
- MyVaccx immunotherapy treatment impact on late stage cancer disease(Time to progression after a complete or partial response up to 60 months)